Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company that develops treatments for central nervous system (CNS) disorders. The company has a market capitalization of approximately $12.64 billion. Market capitalization is the total value of a company's shares and is calculated by multiplying the share price by the number of outstanding shares.
The central theme is a significant insider stock sale by a key executive. On June 9, 2026, CEO Herriot Tabuteau sold 49,670 shares of Axsome Therapeutics at a price of $241.01 each. This transaction totaled approximately $11.97 million. Following the sale, Tabuteau's ownership in the company stands at 7,229 shares.
This insider sale occurs as the company is active on the commercial front. As highlighted by MarketBeat, Axsome Therapeutics is preparing to launch its drug Auvelity for treating Alzheimer's disease agitation. The company's Chief Operating Officer confirmed this near-term focus while also continuing to expand Auvelity's use for major depressive disorder.
The company's stock performance is performing strongly, recently hitting a new 52-week high of $246.41. The stock price is currently priced at $245.64, a daily increase of 4.47%. This activity follows the company's presentation at the Goldman Sachs 47th Annual Global Healthcare Conference, where a transcript was made available.
Additionally, as reported by GlobeNewswire, Axsome Therapeutics has resolved all patent litigation for its product SUNOSI. The settlement allows five companies to sell generic versions of the drug starting as early as March 2040. This removes legal uncertainty for one of its key commercial products.
